EZH2 Gene Function
Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit
Overview
EZH2 is the catalytic methyltransferase within Polycomb repressive complex 2. It places the H3K27me3 chromatin mark and can silence gene programmes; both activating mutations and context-dependent loss of EZH2 function occur in cancer.
Molecular Mechanism
Detailed mechanism data is not yet available for EZH2.
Key Pathways
- ·Polycomb repression
- ·H3K27 methylation
- ·Chromatin regulation
Disease Associations
- ·Germinal-centre lymphoma
- ·Myeloid malignancies
- ·Multiple solid tumours
Research Activity
EZH2 is an actively studied target: about 20+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track EZH2 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About EZH2
What does EZH2 do?
EZH2 participates in Polycomb repression, H3K27 methylation, Chromatin regulation. EZH2 is the catalytic methyltransferase within Polycomb repressive complex 2. It places the H3K27me3 chromatin mark and can silence gene programmes; both activating mutations and context-dependent loss of EZH2 function occur in cancer.
Why is EZH2 relevant to cancer research?
Its reported relevance includes Germinal-centre lymphoma, Myeloid malignancies, Multiple solid tumours. The exact alteration, assay and disease context determine what a result can support.